Biogen Valuation

BIIB Stock  USD 226.40  1.15  0.51%   
At this time, the firm appears to be undervalued. Biogen Inc shows a prevailing Real Value of $249.15 per share. The current price of the firm is $226.4. Our model approximates the value of Biogen Inc from analyzing the firm fundamentals such as Current Valuation of 38.84 B, profit margin of 0.12 %, and Return On Equity of 0.0805 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Biogen's valuation include:
Price Book
1.9465
Enterprise Value
38.8 B
Enterprise Value Ebitda
17.2165
Price Sales
2.9289
Forward PE
13.0039
Undervalued
Today
226.40
Please note that Biogen's price fluctuation is very steady at this time. Calculation of the real value of Biogen Inc is based on 3 months time horizon. Increasing Biogen's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Biogen is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Biogen Stock. However, Biogen's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  226.4 Real  249.15 Target  330.76 Hype  224.34
The real value of Biogen Stock, also known as its intrinsic value, is the underlying worth of Biogen Inc Company, which is reflected in its stock price. It is based on Biogen's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Biogen's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
203.76
Downside
249.15
Real Value
250.91
Upside
Estimating the potential upside or downside of Biogen Inc helps investors to forecast how Biogen stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Biogen more accurately as focusing exclusively on Biogen's fundamentals will not take into account other important factors:
Earnings
Estimates (0)
LowProjectedHigh
3.433.996.04
Details
Hype
Prediction
LowEstimatedHigh
222.58224.34249.04
Details
35 Analysts
Consensus
LowTarget PriceHigh
300.99330.76367.14
Details
Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Biogen's intrinsic value based on its ongoing forecasts of Biogen's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Biogen's closest peers. If more than one evaluation category is relevant for Biogen we suggest using both methods to arrive at a better estimate.

Biogen Cash

723.1 Million

Biogen Valuation Trend

Comparing Biogen's enterprise value against its market capitalization is a good way to estimate the value of Biogen Inc uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.

Biogen Revenue by Product

Biogen Total Value Analysis

Biogen Inc is currently forecasted to have valuation of 38.84 B with market capitalization of 32.96 B, debt of 7.34 B, and cash on hands of 4.91 B. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Biogen fundamentals before making equity appraisal based on enterprise value of the company
  Takeover PriceMarket CapDebt ObligationsCash
38.84 B
32.96 B
7.34 B
4.91 B

Biogen Investor Information

About 93.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.95. Some equities with similar Price to Book (P/B) outperform the market in the long run. Biogen Inc recorded earning per share (EPS) of 7.99. The entity had not issued any dividends in recent years. The firm had 3:1 split on the 18th of January 2001. Based on the analysis of Biogen's profitability, liquidity, and operating efficiency, Biogen Inc is doing better financially today then in previous quarter. It has a moderate odds of reporting better financial numbers in August.

Biogen Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Biogen has an asset utilization ratio of 36.64 percent. This suggests that the Company is making $0.37 for each dollar of assets. An increasing asset utilization means that Biogen Inc is more efficient with each dollar of assets it utilizes for everyday operations.
 
Black Monday
 
Oil Shock
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid

Biogen Ownership Allocation

Biogen holds a total of 145.6 Million outstanding shares. The majority of Biogen Inc outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Biogen Inc to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Biogen. Please pay attention to any change in the institutional holdings of Biogen Inc as this could imply that something significant has changed or is about to change at the company. Please note that on April 5, 2024, Representative Ro Khanna of US Congress acquired under $15k worth of Biogen Inc's common stock.

Biogen Profitability Analysis

The company reported the previous year's revenue of 9.84 B. Net Income was 1.16 B with profit before overhead, payroll, taxes, and interest of 7.9 B.
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Biogen's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Biogen and how it compares across the competition.

About Biogen Valuation

The stock valuation mechanism determines Biogen's current worth on a weekly basis. Our valuation model uses a comparative analysis of Biogen. We calculate exposure to Biogen's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Biogen's related companies.
Last ReportedProjected for Next Year
Gross Profit7.3 B3.9 B
Pretax Profit Margin 0.13  0.14 
Operating Profit Margin 0.13  0.14 
Net Profit Margin 0.12  0.12 
Gross Profit Margin 0.74  0.51 

Biogen Growth Indicators

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
Common Stock Shares Outstanding145.6 M
Quarterly Earnings Growth Y O Y0.011
Forward Price Earnings13.0039

Biogen Current Valuation Indicators

Valuation refers to the process of determining the present value of Biogen Inc and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Biogen we look at many different elements of the entity such as Biogen's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation. Biogen's valuation analysis is also a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Biogen's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Biogen, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Biogen's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Biogen's worth.

Complementary Tools for Biogen Stock analysis

When running Biogen's price analysis, check to measure Biogen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biogen is operating at the current time. Most of Biogen's value examination focuses on studying past and present price action to predict the probability of Biogen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biogen's price. Additionally, you may evaluate how the addition of Biogen to your portfolios can decrease your overall portfolio volatility.
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes